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Abstract
Anemia is an underrecognized but characteristic feature of chronic kidney disease (CKD),
associated with significant cardiovascular morbidity, hospitalization, and mortality. Since their
inception nearly two decades ago, erythropoiesis-stimulating agents (ESAs) have revolutionized the
care of patients with renal anemia, and their use has been associated with improved quality of life
and reduced hospitalizations, inpatient costs, and mortality. Hemoglobin targets ≥13 g/dL have
been linked with adverse events in recent randomized trials, raising concerns over the proper
hemoglobin range for ESA treatment. This review appraises observational and randomized studies
of the outcomes of erythropoietic treatment and offers recommendations for managing renal
anemia in the primary care setting.
Background
Anemia, a common manifestation of chronic kidney dis-
ease (CKD), results primarily from inadequate renal secre-
tion of erythropoietin [1,2]. The prevalence and severity
of anemia worsen steadily as CKD advances (Figure 1) [3].
More than 30% of patients already have hemoglobin
(Hb) levels <12 g/dL by Stage 3 CKD [3] when the esti-
mated glomerular filtration rate (eGFR) falls below 59 ml/
min/1.73 m2, and many patients develop anemia before
their CKD is diagnosed [3,4]. In patients with CKD not
requiring dialysis, untreated anemia increases cardiovas-
cular risk [5-7], hospitalization [8], and all-cause mortal-
ity, [9] and diminishes health-related quality of life [10]
and exercise capacity [11,12]. Heightened risk for progres-
sion of kidney failure has also been linked to untreated
anemia of CKD. Thus, management of anemia through-
out the CKD continuum is essential [1,2,13].
As renal disease often remains asymptomatic until eGFR
falls well below 60 mL/min/1.73 m2, CKD, as well as its
attendant anemia, remains underrecognized [14-16].
Once early CKD is diagnosed, the complexities of manag-
ing multiple comorbidities, such as uncontrolled diabe-
tes, hypertension, hyperlipidemia, and cardiac disease,
can displace clinical attention from anemia [17].
Traditionally, primary care physicians (PCPs) have been
less inclined to manage anemia of CKD and have often
relegated anemia treatment to a nephrologist [17-19].
However, recent claims data suggest that more than 60%
of commercially insured patients with CKD-related ane-
mia are treated exclusively by PCPs [17,19], whereas
patients using Medicare [18] or Veterans' Administration
services [20] are more likely to be managed by nephrolo-
gists prior to dialysis onset. Rapid increases in the end-
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stage kidney disease population [21] have leveled off in
recent years [22]; nevertheless, the aging baby boomer
generation, coupled with the epidemic of obesity and dia-
betes, are predicted to increase the total burden of kidney
disease [23]. Nephrologists bear a formidable share of the
responsibility for managing advanced CKD [24] and fre-
quently become sole providers of primary care to dialysis
patients [25]. The ratio of dialysis recipients to nephrolo-
gists is predicted to exceed 160:1 by 2010 [24]. This
impending shortage highlights the need for PCP manage-
ment of early CKD and its consequences.
For patients with CKD, the risk of death from cardiovascu-
lar complications exceeds the risk of progressing to renal
replacement therapy [26,27]. In a managed care study
[28] of 13,796 patients with eGFR values of 15–90 mL/
min/1.73 m2, 11,278 were in Stage 3 CKD and only 777
in Stage 4, reflecting the competing risks of cardiovascular
death and CKD progression. Stage 4 CKD patients of this
cohort died at a higher rate every year than age- and sex-
matched controls without CKD [28].
The recognition that Stage 3 CKD patients (estimated at
some 6 million in the US) are more likely to die than to
live long enough to reach end stage underscores the need
for CKD screening as well as the importance of maintain-
ing a high index of suspicion of occult cardiovascular dis-
ease. PCPs are thus uniquely poised to detect and treat
CKD and its attendant risk factors before complications
develop.
Evidence-based guidelines published by the National Kid-
ney Foundation provide strategies for slowing the progres-
sion of kidney disease [15,16,29], yet a significant
proportion of PCPs do not recognize the importance of
CKD-related anemia and its treatment [17]. In a survey of
304 US physicians, only 78% of internists and only 59%
of family physicians correctly identified Stage 3–4 CKD in
a hypothetical case study [30]. The potential risks and
benefits of treating anemia of CKD in patients not on dial-
ysis are presented here, with particular emphasis on cardi-
ovascular effects, the rate of CKD progression, and the
implications of recent clinical trials. Fortunately, anemia
is one of the most treatment-responsive complications of
CKD, and its adverse physiologic sequelae can be pre-
vented or delayed by more timely identification and man-
agement.
Review
Prevalence of anemia in CKD
Estimates suggest that eleven percent of adults in the US
population have CKD [31] – an alarming prevalence
[32,33] fueled primarily by the diabetes epidemic and an
aging population that better survives longstanding heart
disease [33]. US Renal Data System projections predict
that nearly 500,000 people will have end-stage renal dis-
ease in 2010, compared with 431,000 in 2002 [34] and
286,000 in 1995 [35]. The cost of caring for CKD of all
stages will soon exceed the cost of the Medicare renal
replacement program itself [26,36]. Thus, reducing the
burden of CKD and its comorbidities (including anemia)
early in their course is a critical public health need.
Anemia of CKD (defined as Hb ≤12.0 g/dL) becomes
increasingly prevalent as kidney function declines, rang-
ing from approximately 27% in Stage 1 to 76% in Stage 5
(Figure 1) [3,32]. In the Prevalence of Anemia in Early
Renal Insufficiency study [3], 47.7% of patients with CKD
not requiring renal replacement had Hb ≤12 g/dL. Female
sex (especially before menopause) [3], African-American
race [3,32,37], and diabetes [3] are independent risk fac-
tors for anemia at each stage of CKD. Anemia is less com-
mon in CKD resulting from glomerulonephritis, multiple
myeloma (dysproteinemia) [3], or polycystic kidney dis-
ease [38,39].
Pathophysiology of anemia of CKD
Anemia of CKD arises primarily from a progressive failure
of kidney endocrine function. Peritubular cells in the kid-
ney cortex function as oxygen sensors controlling red cell
mass. Renal tissue hypoxia triggers hypoxia-inducible fac-
tor signaling, which, in turn, up-regulates erythropoietin
production [40] to stimulate division and differentiation
Prevalence of anemia severity stratified by stage of chronic  kidney disease Figure 1
Prevalence of anemia severity stratified by stage of 
chronic kidney disease. Adapted from McClellan et al., 
2004 [3].Osteopathic Medicine and Primary Care 2007, 1:14 http://www.om-pc.com/content/1/1/14
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of red cell precursors. In anemic but otherwise healthy
individuals, this feedback system restores red blood cell
mass and tissue oxygenation; however, in patients with
CKD, one or more of these processes become impaired
[16]. In early CKD, plasma erythropoietin levels may fall
within the normal range, but show a blunted response to
decreasing hematocrit. As CKD advances, the peritubular
cells progressively diminish in number and function, pro-
ducing insufficient erythropoietin to restore and maintain
appropriate red cell mass [2,40].
Anemia of CKD may reflect dysregulated erythropoietin
release as well as loss of peritubular cells. One hypothesis
involves down-regulation of erythropoietin production in
response to a decreased GFR [41]. As functioning nephron
mass decreases, kidney metabolism consumes less oxy-
gen. Because the peritubular cells are not exposed to local
hypoxia, the stimulus to increase erythropoietin produc-
tion is absent and anemia and peripheral hypoxia go
uncorrected [41].
Congestive heart failure (CHF) frequently complicates
CKD and adversely affects erythropoiesis. Moderate-to-
severe CKD [42] has been reported in 50% of patients
with CHF; conversely, approximately 40% of patients
with CKD have CHF [43]. Untreated CHF may contribute
to anemia of CKD both by enhancing chronic inflamma-
tion [44] and by directly inducing kidney damage [45-47]
(Figure 2).
Consequences of untreated anemia of CKD: observational 
studies
Among patients not requiring renal replacement,
untreated anemia of CKD is strongly associated with car-
diovascular [6,7,46,48-50] and renal [51,52] complica-
tions, resulting in increased hospitalizations [8,28] and
mortality [51].
Left Ventricular Hypertrophy
The cardiovascular system compensates for low blood
oxygenation by delivering a greater volume of blood to
the tissues. The necessary adaptive changes – chronic
vasodilation, volume and pressure overload, increased
heart rate, and increased cardiac output – ultimately result
in left ventricular hypertrophy (LVH) [2,7,13], whose
prevalence is estimated at 39% in Stage 2 CKD, 50% in
Stage 3 CKD [6,7], and 60%-74% in Stage 4 [7]. In a Cana-
dian prospective study of patients with creatinine clear-
ance = 25 mL/min to 75 mL/min[7], each 0.5 g/dL Hb
decrease conferred a 32% increased likelihood of develop-
ing LVH [odds ratio = 1.32, 95% confidence interval (CI)
1.10 to 1.69, P = 0.004]. Decreasing Hb was an independ-
ent risk factor for left ventricular growth when the analysis
controlled for residual kidney function [7].
Congestive Heart Failure
Chronic LVH and mechanical heart stress resulting from
anemia contribute to development of congestive heart
failure (CHF) [46]. Anemia has been described as a "mor-
tality multiplier" in patients with comorbid CKD and
CHF [53]. In the ANCHOR study [48] of 59,772 adults
with CHF, 42.6% had anemia at baseline (Hb <12 g/dL
for women, <13 g/dL for men). In this cohort, anemia
showed a graded, independent relationship to mortality
in CHF patients, the risk of death rising from 16% for
12.0–12.9 g/dL to 248% for <9.0 g/d, which compared to
a reference group with Hb 13.0 g/dL to 13.9 g/dL repre-
sents adjusted hazard ratios of 1.16 and 3.48, respectively.
Hb levels in relation to risk showed a J-shaped curve in
this population, not all of whom had CKD; Hb levels
either below 13.0 g/dL or above 17.0 g/dL were associated
with increased risk of hospitalization and mortality [48].
The cardiorenal anemia syndrome Figure 2
The cardiorenal anemia syndrome. Congestive heart 
failure (CHF) is a cause and consequence of CKD. First, CHF 
inflames the heart, liver, and vasculature, creating an influx of 
circulating cytokines that depress erythropoiesis and perturb 
iron metabolism [44]. Second, CHF directly induces kidney 
damage, in which GFR can deteriorate by as much as one mL/
min/month [45–47]. In response to reduced cardiac output, 
blood pressure (and renal perfusion) is maintained by activa-
tion of the renin-angiotensin-aldosterone system. Angi-
otensin II-mediated renal vasoconstriction and increased 
metabolic demands of the kidney result in renal ischemia and 
ultimately tubular cell death [1]. Renal cell death in turn has-
tens anemia through loss of endocrine function. In addition, 
aldosterone-induced salt and water retention leads to an 
increased pre-load on the heart, which increases its rate in 
an attempt to increase output.Osteopathic Medicine and Primary Care 2007, 1:14 http://www.om-pc.com/content/1/1/14
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Coronary Heart Disease
Anemia of CKD contributes to coronary ischemia by
reducing oxygen delivery. In the Atherosclerosis Risk in
Communities (ARIC) study [50], anemia independently
predicted coronary heart disease in CKD patients. Partici-
pants with anemia and elevated serum creatinine (≥1.2
mg/dL in women or ≥1.5 mg/dL in men) had increased
risk for coronary heart disease over 10.5 years of follow-
up (relative risk = 2.74, 95% CI 1.42 to 5.28) [50]. Ele-
vated creatinine without anemia did not significantly
increase coronary risk (relative risk 1.20, 95% CI 0.86 to
1.67) [50].
Progression to Renal Replacement
Untreated anemia of CKD is also associated with
increased risk of progression to renal replacement. In a
retrospective US Veterans' Affairs cohort, each 1.0 g/dL
increase in time-averaged Hb conferred a 26% reduction
in risk for renal replacement (hazard ratio = 0.74, 95% CI
0.65 to 0.84) [51]. Among diabetic nephropathy patients
in the Reduction of Endpoint in NIDDM with the Angi-
otensin II Antagonist Losartan (RENAAL) study [52], Hb
<11.3 g/dL roughly doubled the risk of renal replacement
onset (hazard ratio = 1.99, 95% CI 1.34 to 2.95, 3.4 years
mean follow-up), and every 1 g/dL Hb decrease increased
renal replacement risk by 11% [52].
Treating anemia of CKD in patients not on dialysis: 
interventional studies
Several interventional studies have tested the hypothesis
that treating anemia of CKD with erythropoietic agents
may reduce or reverse cardiac complications and retard
the rate of CKD progression (Tables 1 and 2). This
hypothesis reflects not only the observational associations
between untreated anemia and cardiorenal morbidity, but
also the physiologic connections between anemia and car-
diorenal pathology (Figure 2).
Early interventional studies [47,54-59] supported the
notion that treating anemia with erythropoietic agents
improves cardiac and renal prognosis. Unexpectedly, the
recent randomized controlled trials Correction of Hemo-
globin and Outcomes in Renal Insufficiency (CHOIR)
[60] and Cardiovascular Risk Reduction by Early Anemia
Treatment with Epoetin (CREATE) [61] showed unfore-
seen increases in cardiovascular events [60] and dialysis
initiation [61] among patients assigned to the highest Hb
targets, prompting reexamination of the optimal targets
and appropriate recipients of erythropoietic therapies.
The primary outcome of the US-based CHOIR study (N =
1432), which enrolled CKD patients with eGFR values of
15 to 50 mL/min/1.73 m2 and Hb levels <11 g/dL, was a
composite of death, myocardial infarction, hospitaliza-
tion for heart failure, or stroke [60]. Patients were allo-
cated to a high-Hb group (target, 13.5 g/dL) or a low-Hb
group (target, 11.3 g/dL); Hb goals were achieved and
maintained by titrated dosages of epoetin alfa. The trial
was stopped after a mean follow-up of 16 months, when
the primary outcome was reached by more patients in the
high-Hb than low-Hb group (17.5% vs. 13.5%, P = 0.03).
Significantly more patients in the high-Hb group reported
histories of hypertension (95.8% vs 93.2%; P = 0.03) or
coronary artery bypass grafts (17.4% vs 13.5%; P = 0.05)
at baseline, suggesting an uneven baseline cardiovascular
risk burden between the groups.
The design of the international CREATE study (N = 603)
[61] was similar to CHOIR. Patients with eGFR values of
15.0 mL/min/1.73 m2 to 35.0 mL/min/1.73 m2 and Hb
levels of 11 g/dL to 12.5 g/dL were randomized to receive
early epoetin beta therapy to an Hb target of 13 g/dL to 15
g/dL or deferred epoetin beta therapy initiated when Hb
levels fell below 10.5 g/dL. The primary endpoint was a
composite of eight cardiovascular events. During an aver-
age follow-up of three years, the likelihood of a first cardi-
ovascular event was not statistically different in the high-
Hb group than in the low-Hb group (19.3% vs. 15.6%, P
= 0.20) [61]. Because the event rate in the low-Hb group
was about half that expected, CREATE may be underpow-
ered to detect differences in cardiovascular outcomes [62].
The differences between the CHOIR and CREATE results
and those of earlier studies invite assessment of the factors
underlying the differences and their implications for ane-
mia treatment in the CKD population not requiring renal
replacement therapy.
Cardiovascular Benefits and Risks
Data from both the CHOIR [60] and CREATE [61] studies
have generated concern that Hb targets >13 g/dL are asso-
ciated with increased incidence of cardiovascular compli-
cations and serious adverse events. In CHOIR, 125
endpoint events (composite of death, myocardial infarc-
tion, hospitalized CHF without dialysis, or stroke)
occurred in the high-Hb group versus 97 events in the
low-Hb group (HR, 1.34; 95% CI, 1.03 to 1.74; P = 0.03).
CHOIR's surprising results echo those of an earlier pro-
spective trial [63] in dialysis patients that was terminated
early because of a trend toward higher rates of death and
first non-fatal myocardial infarction with Hct targets of
42% versus 30%. Nevertheless, the lowest mortality rates
in the latter study occurred in those patients with the high-
est Hct (32–42%).
In CHOIR [60], the lower Hb target (11.3 g/dL) was asso-
ciated with a significantly higher incidence of myocardial
infarction reported as an adverse event than the higher Hb
target (13.5 g/dL) (10 patients [1.5%] vs 19 patients [3%],
P = 0.05).O
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Table 1: Effects of subcutaneous titrated dosages of erythropoietin on cardiovascular endpoints in patients with CKD not on dialysis
Reference 
(study design)
Level of renal function; study 
duration
No. of pts Treatment regimen Endpoint Outcome
Left ventricular hypertrophy
Ayus et al. [54] (uncontrolled) CrCl 10–30 mL/min (diabetic) or 
20–40 mL/min (nondiabetic); 
6 mo
40 (Hb <10 g/dL) EPO to 12 g/dL Change-from-baseline LVMI In anemic pts, LVMI decreased vs baseline (142 vs 157 g/m2;P = 0.007) as Hb 
increased from 9.1 to 11.3 g/dL (P = 0.001).
61 (Hb>10 g/dL) Standard care
CREATE study [61] (r) GFR 15–35 mL/min/1.73 m2, Hb 
11.0–12.5 g/dL;3 yrs
300 EPO to 13–15 g/dL Composite of 8 cardiovascular 
events (primary), LVMI 
(secondary)
Baseline LVMI:
high-Hb group, 120.3 ± 35.0 g/m2
low-Hb group, 118.0 ± 34.3 g/m2
Change at year 1:
High-Hb group, -4.6 g/m2
Low-Hb group, -3.3 g/m2; P = 0.59
Change at year 2
High-Hb group, -6.4 g/m2
Low-Hb group, -7.8 g/m2
300 EPO to 10.5–11.5 g/dL
Levin et al. [56] (r) 24 mo 78 Early EPO to Hb 12–14 g/dL Mean change-from-baseline LVMI Mean LVMI change from baseline:
early EPO, +0.37 g/m2
deferred EPO, +5.21 g/m2
58 Deferred EPO to 9.0–10.5 g/dL
Roger et al. [57] (r, mc, uncontrolled) CrCl 15–50 mL/min, Hb 11.0–
12.0 g/dL (in women) and 11–13 
g/dL (in men);2 yr or until 
dialysis
75 EPO to Hb 12–13 g/dL Mean change-from baseline LVMI No statistically significant between group changes in LVMI over 2 years.
Based on per-protocol Hb levels:
Change from baseline LVMI:
Low Hb group +14 g/m2
High Hb group -1 g/m2.
80 EPO to Hb 9–10 g/dL
Congestive heart failure
Mancini et al. [77] (r) SrCr<2.5 mg/dL, NYHA 
functional class III-IV, 
Hct<35%;3 mo
15 EPO 15 000–30 000/wk Blood and exercise parameters Changes from baseline:
EPO group:
Peak VO2 11.0 to 12.7 mL·min-1·kg-1, P < .05 Exercise duration 590 to 657s, 
P < 0.004
Placebo group: no significant changes
8P l a c e b o
Silverberg et al. [45] (retrospective) Mean NYHA 3.66, SrCr 
2.6 mg/dL, Hct 30%, Hb
10 g/dL;>6 mo
26 EPO + IV iron to Hb 12 g/dL NYHA functional status, LVEF, 
healthcare utilization
Changes from baseline:
Functional status 3.7 to 2.7, P < 0.05
LVEF 28% to 35%, P < 0.001
No. of hospitalizations/pt 2.7 to 0.2, P < 0.05).
Silverberg et al. [47] (r) NYHA class III-IV, LVEF ≤40%, 
Hb 10–11.5 g/dL, 50% with 
CKD; 8.2 mo
16 EPO + IV iron to Hb ≥12.5 g/dL NYHA functional status, LVEF, 
furosemide requirements, 
healthcare utilization
Changes from baseline:
EPO + iron group:
NYHA class, 42.1% improvement LVEF: +5.5%
Length of hospitalization: -79%
Standard care group:
NYHA class: 11% worsening
LVEF: -5%
Length of hospitalization: +58%
16 Standard care
Silverberg et al. [46] (nr) NIDDM or no NIDDM plus 
severe CHF, GFR decline 
>1 mL/min/mo; 11.8 mo
84 (NIDDM) EPO to Hb 12.5 g/dL + IV iron 
PRN
NYHA functional class; VAS for 
fatigue and breathlessness; LVEF
Changes from baseline:
NIDDM pts:
NYHA functional class 35% improvement LVEF +7%
non-NIDDM pts:
NYHA functional class:
32% improvement LVEF +12%
No statistically significant differences between NIDDM and non-NIDDM.
95 (no NIDDM)
Silverberg et al. [78] (nc) Symptomatic CHF despite 
optimal therapies, 
Hb<12 g/dL,91% had CKD 
(CrCl <60 mL/Min);20.7 mo
78 EPO + PRN IV iron to Hb 13 g/dL NYHA functional class, LVEF, 
healthcare utilization
Changes from baseline: (all P < 0.01). NYHA class 2.5 (vs 3.7), LVEF 37% 
(vs 33%); No. of hospitalizations 0.7/year (vs 2.7/year)
CrCl = creatinine clearance; db = double-blind; EPO = epoetin; GFR = glomerular filtration rate; Hct = hematocrit; IV = intravenous; LOHS = length of hospital stay; LVEF = left ventricular ejection 
fraction; LVMI = left ventricular mass index; mc = multicenter; mo = months; nc = noncomparative; NYHA = New York Heart Association; PLA = placebo; PRN = as required; pts = patients; r = 
randomized; SrCr = serum creatinine; VAS = visual-analog scale; wk = week.O
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Table 2: Effects of subcutaneous titrated dosages of erythropoietin in patients not on dialysis on progression to renal replacement therapy
Reference 
(study design)
Level of renal function; trial duration No. of pts Treatment regimen Endpoint Outcome
Dean et al. [55] 
(retrospective)
eGFR 30–59 mL/min/1.73 m2 (n = 71)
eGFR <29 mL/min/1.73 m2 (n =51)
Hb = 10–11.9 g/dL or 8.0–9.9 g/dL
122 Only pts 
with ≥8 EPO 
doses included
EPO (Hb targets, doses not 
specified
Change in least-squares slope 
of inverse serum creatinine 
clearance vs time before and 
after EPO
Baseline eGFR 30–59 ml/min/1.73 m2:
Pre-EPO rate, dL/mg/yr:
-0.0981 (95% CI, -0.12, -0.07)
Post-EPO rate, dL/mg/yr: -0.0692 (95% CI, -0.09, -0.04)
Weighted mean difference, dL/mg/yr: 0.0454 (95% CI, 0.0150, 0.0757)
Baseline eGFR <29 ml/min/1.73 m2:
Pre-EPO rate, dL/mg/yr: -0.0899 (95% CI, -0.12, -0.06)
Post-EPO rate, dL/mg/yr: -0.0416 (95% CI, -0.06, -0.02)
Weighted mean difference, dL/mg/yr: 0.0493 (95% CI, 0.0272, 0.0679)
Overall:
Pre-EPO rate, dL/mg/yr: -0.0937 (95% CI, -0.11, -0.08)
Post-EPO rate, dL/mg/yr: -0.0569 (95% CI, -0.07, -0.04)
Weighted mean difference, dL/mg/yr: 0.0475 (95% CI, 0.0272, 0.0679) P < 0.05
CREATE study [61] (r) eGFR 15–35 mL/min/1.73 m2, Hb 
11.0–12.5 g/dL;3 yrs
300 EPO to 13–15 g/dL Time to dialysis (secondary) 
eGFR also assessed
Change of mean eGFR from baseline:
Year 1:
High-Hb group -3.6 ± 6.7 mL/min
Low-Hb group -3.1 ± 5.3 mL/min
Time to dialysis was significantly shorter in high-Hb group (P = 0.3)
300 EPO to 10.5–11.5 g/dL
Gouva et al. [58] (r, mc) SrCr 2–6 mg/dL (eGFR not given), Hb 
9.0–11.6 g/dL;22.5 mo
45 Early EPO to Hb≥3 g/dL Composite of doubling of 
baseline SrCr, renal 
replacement or death
Composite endpoint: Early EPO pts, 29% Deferred EPO pts, 53%; P = 0.0078
Renal replacement: Early EPO pts, 22% Deferred EPO pts, 42%; P = 0.011
43 Deferred EPO when 
Hb<9.0 g/dL
Jungers et al. [59] (c-cs) Predialysis (CrCl ≤15 mL/min) pts 
(eGFR not given); 24 mo
20 (Hb<10 g/dL) EPO to 11.5 g/dL Change-from-baseline rate of 
decline in creatinine clearance, 
time to dialysis
Rate of change in creatinine clearance, mL/min/1.73 m2/month: EPO group:
Baseline -0.36 ± 0.16
End of study -0.26 ± 0.15 (P < .05)
Standard care group:
Baseline -0.55 ± 0.48
End of study -0.57 ± 0.44
Time to dialysis: EPO group 16.2 ± 11.9 mo
Standard care group 10.6 ± 6.1 mo (P < 0.01).
43 (Hb>10 g/dL) Standard care
Kuriyama et al. [79] (r) SrCr 2–4 mg/dL (eGFR not given), 
Hematocrit<30%;28 mo median follow-up
31 Standard care Doubling of baseline SrCr Doubling of baseline SrCr
EPO, 52% of pts Standard care, 84% of pts
Nonanemic control, 60% of pts
Progression to dialysis:
EPO, 33% of pts
Standard care, 65% of pts (P = 0.008)
Nonanemic control, 37% of pts
42 EPO to Hct 33–35%
SrCr 2–4 mg/dL, Hematocrit>30%;28 mo 
median follow-up
35 Nonanemic control
Rossert et al. [66] 
(r, mc, uncontrolled)a
Iothalamate GFR 25–60 mL/min; 40 mo 108 EPO for Hb 14–15 g/dL (men) 
and 13–14 g/dL (women)
Change-from-baseline GFR as 
estimated by iohexol clearance
GFR change:
High Hb group -0.058 mL/min/1.73 m2
Low Hb group -0.081 mL/min/1.73 m2.
No significant difference between groups
133 PRN EPO for Hb 11–12 g/dL
Silverberg et al. [46] (nr) Cockcroft-Gault eGFR decline >1 mL/min 
per mo; 11.8 mo
84 (NIDDM) EPO to Hb 12.5 g/dL + IV 
Iron PRN
SrCr and CrCl 
(secondary endpoints)
GFR decline halted in both groups
95 (no NIDDM)
a Because of labeling changes for EPO, this study terminated after 7.4 and 8.3 months of maintenance in the high and low Hb group, respectively.
c-cs = case-control study; CHF = congestive heart failure;CrCl = creatinine clearance; db = double-blind; EPO = epoetin; (e)GFR = (estimated) glomerular filtration rate; Hct = hematocrit; mc = 
multicenter; IV = intravenous; mo = months; NIDDM = noninsulin-dependent diabetes mellitus; nr = nonrandomized; PLA = placebo; PRN = as required; pts = patients; r = randomized; SrCr = serum 
creatinine; wks = weeks.Osteopathic Medicine and Primary Care 2007, 1:14 http://www.om-pc.com/content/1/1/14
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In CREATE [61], the high-Hb group reported a greater
incidence of hypertensive episodes (89 patients [30%] vs
59 patients [20%]; P < 0.005) and headaches (31 patients
[10%] vs 16 patients [5%]; P = 0.03) in comparison with
the low-Hb group. These findings, together with earlier
reports of hypertension in ESA-treated CKD patients
[58,64-67] emphasize the need to monitor blood pressure
carefully during erythropoietic treatment. Current labe-
ling of approved agents warns against beginning anemia
treatment in the presence of uncontrolled hypertension
[68,69].
The currently ongoing Trial to Reduce Cardiovascular
Events with Aranesp (TREAT) [70] is a double-blind study
comparing darbepoetin alfa treatment (Hb target, 13 g/
dL) versus placebo in patients with type 2 diabetes and
CKD to assess effects on cardiovascular morbidity due to
acute myocardial ischemia. Placebo recipients are eligible
for a rescue darbepoetin administration only if their Hb
falls below 9 g/dL. TREAT has currently enrolled 3500 of
4000 planned patients [71] – more than CREATE and
CHOIR combined. Patients will be followed until the
required number of endpoint events for analysis have
accrued (i.e., TREAT is an event-driven study). Its Data
Safety Monitoring Board recently evaluated interim
results in view of CREATE, CHOIR, and the March 2007
Food and Drug Administration (FDA) advisory [72,73]
and allowed TREAT to continue [71].
Renal Benefits and Risks
When erythropoietic agents were first introduced, animal
data suggesting a potential adverse effect on renal disease
progression was a focus of concern. Subsequent research
linked this effect with increases in blood pressure associ-
ated with rapidly rising Hb levels, an effect that was pre-
vented by appropriate control of Hb and blood pressure.
A recent review suggests that treating anemia of CKD does
not hasten progression to renal replacement [74]; indeed,
some studies point to possible renoprotection (Table 2).
In a retrospective study of US veterans [55], the rate of
decline in kidney function (least-squares slope of the
reciprocal of serum creatinine) was almost halved after
the onset of epoetin use as compared with the pre-treat-
ment rate. In a 2004 randomized study [58] comparing
epoetin treatment targeted to Hb >13 g/dL with deferred
treatment beginning at <9 g/dL, roughly half as many
patients required renal replacement in the early group (10
of 45 patients) as in the late group (18 of 43 patients).
In CREATE [61], although the rates of eGFR change did
not differ between groups, a significantly higher rate of
progression to dialysis occurred in patients assigned to a
high-Hb level (13 to 15 g/dL) than a low-Hb level (10.5
to 11.5 g/dL). In CHOIR [60], in contrast, proportions of
patients requiring renal replacement did not differ
between groups with Hb targets of 11.3 or 13.5 g/dL.
There is a paucity of information on the effect of anemia
treatment on measured GFR. Effects of anemia treatment
on renal function were assessed by disparate methods
among the studies cited in Table 2 and those in the
Cochrane systematic review [67]. Discordances among
renal results in CREATE, CHOIR, and previous studies
point to the need for a further randomized trial of anemia
therapy in which change in the rate of decline in measured
GFR is a primary endpoint.
Cognition and Quality of Life
In patients on dialysis, untreated anemia can result in
objective cognitive deficits [75], and treatment of anemia
is associated with improved cognitive and social function-
ing [76]. Thus, cognitive and quality-of-life effects have
also been assessed in patients at earlier stages of CKD
receiving anemia treatment. A meta-analysis in this popu-
lation associates erythropoietin use with improved physi-
cal function, energy, sense of well-being, and ability to
work [67]. In CREATE, mean quality-of-life scores were
higher in the normalized Hb group (13.0 g/dL to 15.0 g/
dL) than the low-Hb group (10.5 g/dL to 11.5 g/dL) dur-
ing the first year and became similar between groups
thereafter [61]. In CHOIR, quality of life did not differ
between Hb target groups. Thus, improvement in quality
of life with erythropoietic treatment may be intuitive but
is not yet proven.
Management of Adults with Anemia of Chronic Kidney 
Disease
Clinical Evaluation and Diagnosis
Screening for anemia and other comorbidities is essential
for patients diagnosed with Stage 3 CKD [16]. The course
of CKD is often gradual (years to decades), and decline in
Hb, like decline in eGFR, may be evident only with peri-
odic evaluation. Annual determination of renal function
and Hb levels may suffice for slowly progressing or early
CKD [16]. Patients with moderate-to-severe CKD may
require more frequent Hb monitoring since the likelihood
of anemia is greater in this population; more frequent
monitoring (at least monthly) is also required during
treatment with stimulants of erythropoiesis. Patients with
an eGFR below 30 mL/min/1.73 m2 are considered appro-
priate for referral to a nephrologist, and many PCPs and
nephrologists prefer a higher eGFR referral trigger as Stage
3 approaches. It is prudent to screen for anemia in CKD
patients during and after acute episodes of uncontrolled
comorbid disease (eg, poor glycemic control).
All patients with independent risk factors for CKD-related
anemia warrant close hematologic evaluation during fol-
low-up clinic visits. In addition, diabetic patients are twiceOsteopathic Medicine and Primary Care 2007, 1:14 http://www.om-pc.com/content/1/1/14
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as likely to develop anemia as their nondiabetic counter-
parts at the same level of renal function [37,70], and the
prevalence of anemia in patients with cardiovascular dis-
ease is also significant [42,43]. Patients should also be
checked for malnutrition and vitamin deficiency syn-
dromes.
A Hb level below 12.0 g/dL in women or 13.5 g/dL in men
warrants clinical work-up for anemia (Table 3). In gen-
eral, CKD-related anemia is normochromic and normo-
cytic with bone marrow of normal cellularity. With
impaired production and/or activity of erythropoietin, the
anemia is usually hypoproliferative, as determined by the
absolute reticulocyte count.
Treatment
While the propriety of treating anemia of CKD is well
established to within a Hb target range of 11–12 g/dL, full
normalization of Hb in these patients remains controver-
sial, and benefits remain unproven. New guidelines pub-
lished by the Kidney Disease Outcomes Quality Initiative
(KDOQI) in August 2007 recommend a Hb target range of
11–12 g/dL for patients with CKD [29]. The CHOIR [60]
and CREATE [61] studies indicate evidence of risk and no
evidence of benefit from treating to Hb levels >13.0 g/dL
as compared with ≤12 g/dL. A 2007 FDA advisory [72,73]
recommends maintaining Hb within the range of 10–12
g/dL. Evidence reviewed in the KDOQI guidelines [16,29]
suggests that treating to maintain Hb at or above 11 g/dL
provides quality of life benefits without increased adverse
events. Routine monitoring (preferably monthly) of
blood pressure, renal function, Hb, and iron studies is
required to obtain the most effective regimen of erythro-
poietic therapy [68,69]. The current FDA advisory [72,73]
recommends more frequent Hb monitoring (twice
weekly) during initial correction of anemia and after ESA
dose changes.
Table 3: Management of anemia in patients with chronic kidney disease (CKD) [16, 29]
Intervention Significance
Identification and clinical evaluation
Screening Patients with CKD should be evaluated for the presence of anemia once GFR reaches 60 mL/min. 
Kidney function (and Hb level) should be assessed in all patients with cardiovascular disease and 
diabetes.
Hematological work-up
Hb Determines severity of anemia. Hb is a more reliable surrogate marker than hematocrit. Dosages 
of erythropoietic agents are titrated to the absolute Hb value, taking into account the relative 
increase from the last dosage.
Complete blood count (MCH, MCV, MCHC, 
white blood cell count, platelet count)
Information on: potential folate and vitamin B12 deficiency (high MCV indicative of macrocytosis); 
iron deficiency (low MCH indicative of hypochromia); and capacity of bone marrow function.
Absolute reticulocyte count Determination of proliferative activity
Serum ferritin Assessment of iron storage reserves (target, 200 ng/mL). There is little evidence to suggest 
treating patients with levels >500 ng/mL is worthwhile.
TSAT or Hb content in reticulocytes Iron balance and distribution (TSAT target > 20%).
Treatment
Target risk factors Progression of CKD can be delayed by tight control of blood pressure, blood glucose, and 
proteinuria.
Stimulants of erythropoiesis Recommended in anemic patients to maintain Hb levels between 11.0 g/dL and 12.0 g/dL. Monthly 
follow-up is required to ensure the regimen does not raise Hb >12 g/dL and/or induce 
hypertension.
Iron Oral iron preparations (FeSO4, Niferex, Proferrin, etc.) may be sufficient to raise iron stores, 
though monthly IV iron supplementation may be required to ensure optimal erythropoiesis in 
patients with iron-deficiency anemia. Iron gluconate or iron sucrose are safer than iron dextran, 
which has been associated with anaphylaxis. Emerging IV iron agents are designed to minimize free 
iron and oxidative stress; an emerging oral iron agent utilizes the heme iron receptor in the gut 
for enhanced absorption.
Nutritional supplements Oral supplementation of folate, pyridoxine and vitamin B12 (and other vitamins) is a rational 
choice in malnourished patients.
Androgens Not recommended.
MCH = mean corpuscular hemoglobin; MCV = mean corpuscular volume; MCHC = mean corpuscular hemoglobin concentration, 
Hb = hemoglobin; TSAT = serum transferrin saturation.Osteopathic Medicine and Primary Care 2007, 1:14 http://www.om-pc.com/content/1/1/14
Page 9 of 11
(page number not for citation purposes)
It is essential to control hypertension before and during
stimulated erythropoiesis [72,73]. Determination of
serum ferritin and transferrin saturation is advised before
initiation of erythropoietic therapy and every 1–3 months
during therapy (Table 3) [16]. Patients with stable Hb in
the target range who are receiving a stable dose of an
erythropoietic agent should have their Hb checked
monthly [16]. In iron-deficient patients, oral supplemen-
tation with inorganic iron salts may be sufficient, but
more often parenteral iron is required in the form of iron
gluconate or iron sucrose, which have supplanted iron
dextran because of superior safety profiles. Physiologic
levels of folate, vitamin B12, and pyridoxine can be main-
tained with oral supplementation.
Conclusion
Anemia, a clinical manifestation of reduced kidney func-
tion, is often underrecognized in patients with CKD. Sub-
stantial mortality and morbidity are associated with
advanced CKD, and current evidence suggests that early
proactive multimodal treatment can improve outcomes.
PCPs are uniquely positioned to screen at-risk patients for
early CKD and anemia. In most patients, the severity of
anemia can be easily reduced by use of erythropoietic
agents and intravenous iron as necessary in the primary
care setting. Monthly follow-up is required to evaluate
general cardiorenal health and to ensure that Hb levels do
not overshoot the optimal range of 11–12 g/dL, given cur-
rent questions regarding the optimal Hb target. The bur-
den of CKD and its complications is expected to continue
to increase. With a shortage of nephrologists predicted, an
expanded role for PCPs in the management of CKD and
its attendant anemia may avert this potential public
health crisis.
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